Solvonis Therapeutics (LSE:SVNS) 5-Year EBITDA Growth Rate : -44.60% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Solvonis Therapeutics 5-Year EBITDA Growth Rate?

Solvonis Therapeutics's EBITDA per Share for the six months ended in Jun. 2024 was £-0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was -110.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -44.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Solvonis Therapeutics was 15.70% per year. The lowest was -110.50% per year. And the median was -60.90% per year.

Competitive Comparison of Solvonis Therapeutics's 5-Year EBITDA Growth Rate

For the Specialty Industrial Machinery subindustry, Solvonis Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Solvonis Therapeutics's 5-Year EBITDA Growth Rate Distribution in the Industrial Products Industry

For the Industrial Products industry and Industrials sector, Solvonis Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Solvonis Therapeutics's 5-Year EBITDA Growth Rate falls into.

Solvonis Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Solvonis Therapeutics (LSE:SVNS) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Solvonis Therapeutics 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Solvonis Therapeutics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Solvonis Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

J4I:Germany

Address

Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF

Website

https://www.solvonis.com

Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.

Solvonis Therapeutics Headlines

No Headlines